About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Biosimilar Drug Shows Promise in Breast Cancer Treatment

Font : A-A+

Highlights
  • Biosimilar drug is an identical copy of the original drug that can be manufactured by a different company.
  • A research team from the University of California compared the biosimilar form of trastuzumab drug with the original drug for breast cancer treatment.
  • Biosimilar trastuzumab drug may increase treatment options for breast cancer.

 Biosimilar Drug Shows Promise in Breast Cancer Treatment

Biosimilar form of Trastuzumab was found to show equal response as that of trastuzumab drug used in breast cancer treatment, finds a study from the University of California.

The study was published online in the journal JAMA.

Advertisement


Biosimilar drug is a biological product which is an identical copy of the original drug that is manufactured by a different company.

Biological products include monoclonal antibodies that can be used for cancer treatment. Drugs like trastuzumab improves overall survival and slows down progression of metastatic breast cancer.
Advertisement

The Phase 3 clinical trial of the study was conducted by randomly administering biosimilar trastuzumab drug along with a taxane to breast cancer patients. This was done to compare the response rate and safety after 24 weeks. Chemotherapy drugs were administered following the antibody for 24 weeks, until there were any toxic effects or disease progression.

The response rate after 24 weeks was considered as complete or partial response.

The study findings showed an overall response rate of 70% for biosimilar form of trastuzumab drug when compared to 64% for trastuzumab drug. After 48 weeks, there was no significant difference between biosimilar form and trastuzumab for cancer progression.

Around 99% and 95% of patients had atleast 1 adverse event, between biosimilar and trastuzumab drug.

The authors wrote,"Trastuzumab is not widely available around the world."

"A biosimilar treatment option may increase global access to biologic cancer therapies, provided, among other issues, that the price of the biosimilar is sufficiently inexpensive to enable women in non-high-income countries to access this therapy."

However, further study is required to know the safety and long-term benefit of the drug.

Reference
  1. Hope S. Rugo et.al. MD1 Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer : A Randomized Clinical Trial ; JAMA (2016) doi:10.1001/jama.2016.18305


Source: Medindia

Citations   close

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Drug Toxicity Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Signature Drug Toxicity Breast Cancer Facts Cancer Facts Cancer 

Most Popular on Medindia

Indian Medical Journals The Essence of Yoga Color Blindness Calculator Drug Side Effects Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Noscaphene (Noscapine) Loram (2 mg) (Lorazepam) Blood Donation - Recipients Find a Doctor Selfie Addiction Calculator
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Biosimilar Drug Shows Promise in Breast Cancer Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests